A salt and crystal form of a pyrimidine compound and its preparation method
By developing salts and crystal forms of compound I, particularly multiple crystal forms of fumarate and p-toluenesulfonate, the issues of high efficacy, low toxicity, and pharmaceutical properties of RET inhibitors have been resolved, enabling effective treatment of RET-related diseases.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD
- Filing Date
- 2021-07-23
- Publication Date
- 2026-07-17
AI Technical Summary
Currently, there are no highly effective and low-toxicity RET inhibitors for the treatment of diseases related to RET activity, and crystalline forms lack properties such as bioavailability, physical and chemical stability for pharmaceutical use.
Develop salts and crystal forms of compound I, including multiple crystal forms of fumarate and p-toluenesulfonate, and prepare pharmaceutical compositions for treating related diseases by reacting with inorganic or organic acids to precipitate solids and separating and drying them.
The salt and crystal form of compound I exhibit good RET inhibitory activity, with improved bioavailability and stability, making it suitable for use as a pharmaceutical formulation and providing an effective means of treating RET-related diseases.
Smart Images
Figure CN115702154B_ABST